UroGen Pharma Ltd. — Director's Dealing 2025

Oct 9, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2025-10-08

Reporting Person: Degnan Chris (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-08	Ordinary Shares	M	4483	—	Acquired	4483	Direct
2025-10-08	Ordinary Shares	S	2203	$16.85	Disposed	2280	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-10-08	Restricted Stock Units	$	M	4483	Disposed		Ordinary Shares (4483)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F3: The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025.